The inspection of a Pfizer plant in the Chinese city of Dalian by the US Food and Drug Administration revealed that officials there were keeping a second set of quality and manufacturing records to hide quality failures, the use of expired manufacturing materials and other violations, Bloomberg reported, citing details from an FDA report. Pfizer spokesperson Mackay Jimeson declined to say what products the plant manufactures. The FDA, which typically conducts an inspection of a manufacturing facility before it’s allowed to ship to the US, declined to comment about the report.
You must log in to post a comment.
Yes, I would like to receive emails from China Economic Review. (You can unsubscribe anytime)
Copyright © 2018 SinoMedia Group Limited All rights reserved